TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11466597

Group type: EXPERIMENTAL
Intervention: Intervention group (screening and intervention program)
Number of subjects: 7042

Group type: COMPARATOR
Intervention: Control group (risk screening, general advice)
Number of subjects: 7042

Group type: EXPERIMENTAL
Intervention: Dietary protocol analysis for both adults and children
Number of subjects: 7042
Study: 9434650

Group type: EXPERIMENTAL
Intervention: Telephone interviews
Number of subjects: 325

Group type: COMPARATOR
Intervention: Face-to-face interviews
Number of subjects: 325
Study: 7988089

Group type: EXPERIMENTAL
Intervention: Aspirin (30 to 283 mg)
Number of subjects: 91
Study: 2511610

Group type: EXPERIMENTAL
Intervention: Pirbuterol 20 mg thrice daily for 6 months
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 10
Study: 31351491

Group type: EXPERIMENTAL
Intervention: Povidone-iodine ear wash
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Oral cotrimoxazole
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Standard treatment (dry mopping and ciprofloxacin drops) plus dilute povidone-iodine ear wash
Number of subjects: 280

Group type: COMPARATOR
Intervention: Standard treatment (dry mopping and ciprofloxacin drops) plus placebo
Number of subjects: 280
Study: 28877043

Group type: EXPERIMENTAL
Intervention: One-legged exercise using one leg and both arms
Number of subjects: 28

Group type: COMPARATOR
Intervention: Two-legged exercise using both legs and both arms
Number of subjects: 28
Study: 26277270

Group type: EXPERIMENTAL
Intervention: Bipolar disorder type II
Number of subjects: 33

Group type: COMPARATOR
Intervention: Bipolar disorder type I
Number of subjects: 33
Study: 24120480

Group type: EXPERIMENTAL
Intervention: Perioperative FOLFOX4 chemotherapy (6 cycles of oxaliplatin 85mg/m², folinic acid 200 mg/m² or 100 mg/m², fluorouracil 400 mg/m² bolus and 600 mg/m² continuous infusion)
Number of subjects: 364

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Perioperative FOLFOX4 chemotherapy
Number of subjects: 364
Study: 21145193

Group type: EXPERIMENTAL
Intervention: Group MgSO(4) - 50mg of magnesium sulphate 5% (1.0 mL) added to 25 μg of fentanyl citrate (0.5 mL) and 300 μg of morphine
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control Group S - 25 μg of fentanyl citrate (0.5 mL) + 300 μg of morphine + 1.0 mL of preservative-free 0.9% sodium chloride
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 58
Study: 18287358

Group type: EXPERIMENTAL
Intervention: CLA-rich fat (115 g/d, 5.5 g/d CLA oil, 39.4% cis9, trans11 and 38.5% trans10, cis12)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control fat with a low content of CLA
Number of subjects: 38
Study: 16510465

Group type: EXPERIMENTAL
Intervention: Intracoronary autologous bone marrow cell (BMC) transfer
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control
Number of subjects: 59
Study: 12543892

Group type: EXPERIMENTAL
Intervention: Normal haemoglobin (135-160 g/l)
Number of subjects: 416

Group type: COMPARATOR
Intervention: Subnormal haemoglobin (90-120 g/l)
Number of subjects: 416
Study: 10987585

Group type: EXPERIMENTAL
Intervention: Eptifibatide (180 microg/kg bolus + continuous infusion of 2.0 microg/kg/min for ≤96 h)
Number of subjects: 9449

Group type: EXPERIMENTAL
Intervention: Eptifibatide
Number of subjects: 9449

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9449
Study: 9164283

Group type: EXPERIMENTAL
Intervention: High intensity strength training program
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sedentary control group
Number of subjects: 100
Study: 8011251

Group type: EXPERIMENTAL
Intervention: Potentially antitoxoplasmic drugs (trimethoprim‐sulphamethoxazole, pyrimethamine, dapsone, pyrimethamine‐sulphadoxine, sulphadiazine)
Number of subjects: 499

Group type: COMPARATOR
Intervention: No prophylactic treatment
Number of subjects: 499
Study: 2891797

Group type: EXPERIMENTAL
Intervention: VEPA-M (vincristine, cyclophosphamide, prednisolone, doxorubicin, and methotrexate)
Number of subjects: 163

Group type: COMPARATOR
Intervention: VEPA (vincristine, cyclophosphamide, prednisolone, and doxorubicin)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: VEPA or VEPA-M therapy
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Factors affecting disease-free survival
Number of subjects: 163
Study: 31735048

Group type: EXPERIMENTAL
Intervention: Patient spiritual well‐being (FACIT‐SP Faith subscale)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Patient health‐related quality of life (PDQ‐39)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Caregiver depression (HADS Depression)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Caregiver anxiety (HADS Anxiety)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Caregiver perspective on patient quality of life (QOL‐AD Caregiver Perspective)
Number of subjects: 175
Study: 30761565

Group type: EXPERIMENTAL
Intervention: Nanocurcumin
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 28091969

Group type: EXPERIMENTAL
Intervention: Mental QoL scores (HADS-D)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Mental QoL scores (HADS-A)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Mental QoL scores (SF-36)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Physical QoL scores (SF-36)
Number of subjects: 400
Study: 26600459

Group type: EXPERIMENTAL
Intervention: Immediate treatment with ART for 12 months
Number of subjects: 113

Group type: COMPARATOR
Intervention: Observation and deferred ART
Number of subjects: 113
Study: 23219191

Group type: EXPERIMENTAL
Intervention: Diffusion-weighted imaging (DWI) in patients without chemoradiotherapy
Number of subjects: 21

Group type: COMPARATOR
Intervention: Diffusion-weighted imaging (DWI) in patients after chemoradiotherapy
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Diffusion-weighted imaging (DWI) in adjacent rectum and fat
Number of subjects: 21
Study: 20843978

Group type: EXPERIMENTAL
Intervention: DASH eating pattern
Number of subjects: 31
Study: 18430858

Group type: EXPERIMENTAL
Intervention: Laryngeal phonation CT during /hee/ phonation
Number of subjects: 31

Group type: COMPARATOR
Intervention: Conventional axial CT
Number of subjects: 31
Study: 16551140

Group type: EXPERIMENTAL
Intervention: Couples intervention (n=28)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Comparison group (n=38)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Comparable childless couples (n=13)
Number of subjects: 66
Study: 12691976

Group type: EXPERIMENTAL
Intervention: Evidence-based medicine (EBM) curriculum workshop series (ten sessions) introduced in 2000
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (residents at another FP residency at the same university)
Number of subjects: 0
Study: 10871576

Group type: EXPERIMENTAL
Intervention: 0.7 g protein/kg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 0.8 g protein/kg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 0.9 g protein/kg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 1.0 g protein/kg
Number of subjects: 8
Study: 9107241

Group type: EXPERIMENTAL
Intervention: Transjugular shunt
Number of subjects: 126

Group type: COMPARATOR
Intervention: Endoscopic treatment
Number of subjects: 126
Study: 8256784

Group type: EXPERIMENTAL
Intervention: Live oral cholera vaccine CVD 103‐HgR (5 x 10(8) colony forming units)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Killed Escherichia coli K12 placebo
Number of subjects: 0
Study: 3572463

Group type: EXPERIMENTAL
Intervention: Intensive consolidation chemotherapy (four courses)
Number of subjects: 0
Study: 29292555

Group type: EXPERIMENTAL
Intervention: Klompas algorithm
Number of subjects: 66690

Group type: COMPARATOR
Intervention: Majority of diabetes diagnosis codes being type 1
Number of subjects: 66690

Group type: EXPERIMENTAL
Intervention: Urine acetone test strips criterion
Number of subjects: 66690
Study: 27634417

Group type: EXPERIMENTAL
Intervention: Care Management intervention
Number of subjects: 2500

Group type: EXPERIMENTAL
Intervention: Skills Training intervention
Number of subjects: 2500

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 2500

Group type: EXPERIMENTAL
Intervention: Overall comparison
Number of subjects: 2500
Study: 23752057

Group type: COMPARATOR
Intervention: 18 mcg tiotropium
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 18 mcg tiotropium plus 12 mcg formoterol
Number of subjects: 44
Study: 23398256

Group type: EXPERIMENTAL
Intervention: Heavy media multitaskers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Light media multitaskers
Number of subjects: 0
Study: 20825252

Group type: EXPERIMENTAL
Intervention: Sugammadex 32 mg/kg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Sugammadex 64 mg/kg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Sugammadex 96 mg/kg
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 18279212

Group type: EXPERIMENTAL
Intervention: Nasal flow-synchronized intermittent positive pressure ventilation (NFSIPPV)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Conventional nasal continuous positive airway pressure (NCPAP)
Number of subjects: 63
Study: 16010547

Group type: EXPERIMENTAL
Intervention: Injection of 2 ml of sterile saline into the pack prior to opening
Number of subjects: 47

Group type: COMPARATOR
Intervention: No injection of saline into the pack prior to opening
Number of subjects: 47
Study: 12969670

Group type: EXPERIMENTAL
Intervention: Cross-wound suturing
Number of subjects: 20

Group type: COMPARATOR
Intervention: Unaltered area of the defect (Control)
Number of subjects: 20
Study: 10230828

Group type: EXPERIMENTAL
Intervention: Hygiene program intervention
Number of subjects: 1729

Group type: COMPARATOR
Intervention: Monitoring alone
Number of subjects: 1729
Study: 10160446

Group type: EXPERIMENTAL
Intervention: 300 units/kg
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Hemostasis Management System (HMS)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: RX/DX
Number of subjects: 107

Group type: COMPARATOR
Intervention: Comparison of all methods
Number of subjects: 107
Study: 1678392

Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol (100, 200, 500, 1000 micrograms)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo (identical to salbutamol)
Number of subjects: 7
Study: 6414387

Group type: EXPERIMENTAL
Intervention: Auranofin
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Sodium aurothiomalate (Myocrisin)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 31561331

Group type: EXPERIMENTAL
Intervention: Electrospun PEEU fiber meshes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single fibers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fiber mesh architecture
Number of subjects: 0
Study: 28933609

Group type: EXPERIMENTAL
Intervention: Dual task training program (n=8)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Single task training program (n=6)
Number of subjects: 20
Study: 25598453

Group type: EXPERIMENTAL
Intervention: Intravesical pressure-attenuation balloon
Number of subjects: 63

Group type: COMPARATOR
Intervention: Sham procedure (Control)
Number of subjects: 63
Study: 24346811

Group type: EXPERIMENTAL
Intervention: Extended-release paliperidone (paliperidone ER) 6 mg
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Oral risperidone (mean dose: 4.0 mg)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Switching from oral risperidone to paliperidone ER
Number of subjects: 25
Study: 21701846

Group type: EXPERIMENTAL
Intervention: Walking at preferred stride frequency (PSF)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Walking at stride frequencies other than PSF
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lower stride frequencies
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Walking at PSF
Number of subjects: 12
Study: 21121492

Group type: EXPERIMENTAL
Intervention: Brief cognitive behavioral therapy (CBT) intervention program, conducted over four consecutive 1.5-hour weekly sessions.
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 26
Study: 18159576

Group type: EXPERIMENTAL
Intervention: Tramadol
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tramadol-metamizol
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tramadol-lornoxicam
Number of subjects: 60
Study: 15896432

Group type: EXPERIMENTAL
Intervention: HMB/GLN/ARG
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (nitrogen and calorie balanced mixture of alanine, glutamic acid, glycine, and serine)
Number of subjects: 40
Study: 12387694

Group type: EXPERIMENTAL
Intervention: Cabergoline
Number of subjects: 0
Study: 9594939

Group type: EXPERIMENTAL
Intervention: Terbinafine 250 mg/day
Number of subjects: 372

Group type: COMPARATOR
Intervention: Itraconazole 200 mg/day
Number of subjects: 372
Study: 7751526

Group type: EXPERIMENTAL
Intervention: Antihistamine and anti-inflammatory medicines timed to the day-night temporal pattern in symptom manifestation and intensity.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional equal-interval, equal-dose medication schedules.
Number of subjects: 0
Study: 2693113

Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 401194

Group type: EXPERIMENTAL
Intervention: 30 mg/kg bolus of methylprednisolone
Number of subjects: 0

Group type: COMPARATOR
Intervention: 3 mg/kg bolus of methylprednisolone
Number of subjects: 0
Study: 30975599

Group type: EXPERIMENTAL
Intervention: Laparoscopic pancreatoduodenectomy (LPD)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Open pancreatoduodenectomy (OPD)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Patients with Clavien-Dindo ≥ III complications
Number of subjects: 38

Group type: COMPARATOR
Intervention: Patients without Clavien-Dindo ≥ III complications
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Patients with POPF grade B/C
Number of subjects: 38

Group type: COMPARATOR
Intervention: Patients without POPF grade B/C
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Patients with POPF grade B/C after LPD
Number of subjects: 38

Group type: COMPARATOR
Intervention: Patients with POPF grade B/C after OPD
Number of subjects: 38
Study: 28327526

Group type: EXPERIMENTAL
Intervention: Ser‐Se‐Ly association (n = 45)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (n = 45)
Number of subjects: 90
Study: 25972575

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (50,000 IU/month)
Number of subjects: 275

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 275
Study: 24331203

Group type: EXPERIMENTAL
Intervention: Patient-Family Education (PFE)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Family Partnership Intervention (FPI)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Medication Adherence (MA)
Number of subjects: 117
Study: 21804511

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (no Dexamethasone)
Number of subjects: 60
Study: 19907850

Group type: EXPERIMENTAL
Intervention: Gold-alloy post-core-crowns
Number of subjects: 289

Group type: COMPARATOR
Intervention: Nickel-chromium-alloy post-core-crowns
Number of subjects: 289
Study: 16681474

Group type: EXPERIMENTAL
Intervention: Total hysterectomy (laparoscopic assisted vaginal hysterectomy, N = 32)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Subtotal hysterectomy (supracervical laparoscopic hysterectomy, N = 31)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Total hysterectomy (N = 32)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Subtotal hysterectomy (N = 31)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Minor gynecological surgery (SURG‐CON, N = 30)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Healthy nonsurgical controls (NORM‐CON, N = 40)
Number of subjects: 63
Study: 15484710

Group type: EXPERIMENTAL
Intervention: Endurance athletes
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Power athletes
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Ball game players
Number of subjects: 158

Group type: COMPARATOR
Intervention: Non-athletic subjects
Number of subjects: 158
Study: 11739353

Group type: EXPERIMENTAL
Intervention: Traditional bonesetters (TBS) treatment
Number of subjects: 49

Group type: COMPARATOR
Intervention: Orthodox treatment in hospital
Number of subjects: 49
Study: 9233719

Group type: EXPERIMENTAL
Intervention: Imipenem/cilastatin
Number of subjects: 69

Group type: COMPARATOR
Intervention: Ceftazidime
Number of subjects: 69
Study: 8497353

Group type: EXPERIMENTAL
Intervention: Continuous intrapartum electronic fetal heart rate monitoring (EFM)
Number of subjects: 1428

Group type: COMPARATOR
Intervention: Intermittent auscultation
Number of subjects: 1428
Study: 2828818

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 2 mg naloxone
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 10 mg naloxone
Number of subjects: 9
Study: 31576625

Group type: EXPERIMENTAL
Intervention: Pharmacist-led education and follow-up service (PEFS)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 152
Study: 28591764

Group type: COMPARATOR
Intervention: Isocaloric placebo (P)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Whey protein supplement (W)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: In-home rehabilitation + placebo (R+P)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Rehabilitation + whey protein (R+W)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Testosterone (T)
Number of subjects: 100
Study: 26008820

Group type: EXPERIMENTAL
Intervention: High-protein diet with soluble milk proteins (PRO HP)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: High-protein diet with caseins (CAS HP)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Adequate-protein diet with soluble milk proteins (PRO AP)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Feeding with soluble milk proteins (PRO)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Feeding with caseins (CAS)
Number of subjects: 31
Study: 25399618

Group type: EXPERIMENTAL
Intervention: New combination of retinoids and depigmenting agents
Number of subjects: 30

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 30
Study: 22545614

Group type: EXPERIMENTAL
Intervention: Instruction-based task sets
Number of subjects: 0

Group type: COMPARATOR
Intervention: Maintenance of instructions in declarative working memory
Number of subjects: 0
Study: 20354468

Group type: EXPERIMENTAL
Intervention: Psychomotor therapy (home program and 3 outpatient sessions)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Exercise therapy (home program focusing on pain contingent training of back, abdominal, and leg muscle functional strength and endurance, stretching, and cardiovascular fitness)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Psychomotor therapy
Number of subjects: 107
Study: 18845961

Group type: EXPERIMENTAL
Intervention: 3 doses of 1440 UI of hepatitis A vaccine (HAVRIX) at weeks 0, 4, and 24
Number of subjects: 95

Group type: COMPARATOR
Intervention: 2 doses of hepatitis A vaccine 24 weeks apart
Number of subjects: 95
Study: 16682791

Group type: EXPERIMENTAL
Intervention: Atenolol for 3 months
Number of subjects: 9

Group type: COMPARATOR
Intervention: Healthy subjects (control)
Number of subjects: 9
Study: 14642682

Group type: EXPERIMENTAL
Intervention: Rofecoxib (25 mg/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 10868768

Group type: EXPERIMENTAL
Intervention: Work-site interventions for smoking cessation
Number of subjects: 2106
Study: 8977984

Group type: EXPERIMENTAL
Intervention: 1M depot formulation
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: 3M depot formulation
Number of subjects: 237
Study: 1608405

Group type: EXPERIMENTAL
Intervention: Heparin alone
Number of subjects: 403

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 403

Group type: COMPARATOR
Intervention: Both treatments (Heparin and Aspirin)
Number of subjects: 403

Group type: COMPARATOR
Intervention: Neither treatment (placebo)
Number of subjects: 403
Study: 6204148

Group type: EXPERIMENTAL
Intervention: Na+‐K+‐Mg2+ salt (replacing 35 or 55% of NaCl) for 3-5 weeks in hospitalized patients and 6 months in outpatients
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Na+‐K+‐Mg2+ salt
Number of subjects: 126
Study: 31416744

Group type: EXPERIMENTAL
Intervention: Mindfulness-based psycho-education group programme
Number of subjects: 180

Group type: COMPARATOR
Intervention: Psycho-education group
Number of subjects: 180

Group type: COMPARATOR
Intervention: Treatment-as-usual group
Number of subjects: 180
Study: 28699770

Group type: EXPERIMENTAL
Intervention: Comprehensive rehabilitation consisting of a physical exercise program and psycho-educational consultations
Number of subjects: 210

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Comprehensive rehabilitation
Number of subjects: 210
Study: 26361994

Group type: EXPERIMENTAL
Intervention: Venlafaxine (18.75 mg/day)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 13
Study: 25303140

Group type: EXPERIMENTAL
Intervention: TST (Tuberculin Skin Test)
Number of subjects: 1728

Group type: EXPERIMENTAL
Intervention: QuantiFERON-TB-Gold in-tube test (ELISA)
Number of subjects: 1728

Group type: EXPERIMENTAL
Intervention: T-SPOT.TB test (enzyme-linked immunospot)
Number of subjects: 1728

Group type: EXPERIMENTAL
Intervention: TST
Number of subjects: 1728

Group type: EXPERIMENTAL
Intervention: HIV infection with positive TST
Number of subjects: 1728

Group type: EXPERIMENTAL
Intervention: HIV infection with positive ELISA
Number of subjects: 1728

Group type: EXPERIMENTAL
Intervention: HIV infection with positive enzyme-linked immunospot result
Number of subjects: 1728

Group type: EXPERIMENTAL
Intervention: Preventive chemotherapy
Number of subjects: 1728
Study: 22075016

Group type: EXPERIMENTAL
Intervention: i-gel
Number of subjects: 160

Group type: COMPARATOR
Intervention: LMA Fastrach
Number of subjects: 160
Study: 19809363

Group type: EXPERIMENTAL
Intervention: Valsartan 160 mg once daily for 4 weeks, then randomized to valsartan 160, 320, or 640 mg/day for 26 weeks
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Valsartan 320 or 640 mg/day
Number of subjects: 110

Group type: COMPARATOR
Intervention: Valsartan 160 mg/day
Number of subjects: 110